Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472972 | 0.91 | UTS2R (0.92) | UTS2RALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL1732463 | 0.90 | UTS2R (0.86) | UTS2RMAPK1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1472857 | 0.89 | UTS2R (0.81) | UTS2RSMN1; SMN2MAPK1ALDH1A1KDM4E | |
| SCHEMBL1472602 | 0.89 | UTS2R (0.84) | UTS2RMAPK1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1472319 | 0.88 | UTS2R (0.79) | UTS2RMAPK1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1472930 | 0.88 | UTS2R (1.00) | UTS2RALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL1471678 | 0.88 | UTS2R (0.78) | UTS2RMAPK1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1472805 | 0.87 | UTS2R (0.87) | UTS2RALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL1472782 | 0.87 | UTS2R (0.87) | UTS2RALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL1471758 | 0.86 | UTS2R (0.86) | UTS2RSMN1; SMN2MAPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SMN1; SMN2 2074/4885MAPK1 3510/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SMN1; SMN2 2074/4885MAPK1 3510/4885 |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SMN1; SMN2 2074/4885MAPK1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.